Not Yet Recruiting
PHASE3
INTERVENTIONAL
NCT07139548
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.
Interventions
Name:
RAY1225
Type:
DRUG
Description:
Administered SC
Name:
Semaglutide
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)
TimeFrame:
Baseline,36 Week
Description:
HbA1c is the glycosylated fraction of hemoglobin A.
Trial Information
NCT ID
NCT07139548
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Last Updated
December 15, 2025